These slides covers one of the most common types of acute leukemia in adults. AML makes up 32% of all adult leukemia cases. 1.8% of cancer deaths are caused by AML, meaning that it is quite rare. Xeraya Capital is currently working with Oncomyx and Imago Bio on novel treatments for patients with AML.

1. acute myeloid
leukemia (AML)
Cancer of the Blood & Bone Marrow
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com

2. What Is Acute Myeloid Leukemia (AML)?
Cancer starts when cells in a
part of the body begin to
grow out of control.
Acute myeloid leukemia
(AML) starts in the bone
marrow (the soft inner part of
certain bones, where new
blood cells are made).
Source: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html
Most often, AML develops from cells that
would turn into white blood cells (other
than lymphocytes).

3. Understanding The Bone Marrow
Normally, the bone marrow
makes blood stem cells
(immature cells) that become
mature blood cells over time.
A blood stem cell may become
a myeloid stem cell or a
lymphoid stem cell. A lymphoid
stem cell becomes a white
blood cell.
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

4. The Myeloid Stem Cell
A myeloid stem cell becomes
one of 3 types of mature
blood cells:
• Red Blood Cells – oxygen &
carbon dioxide transport
• White Blood Cells – fight off
infection & disease
• Platelets – form blood clots
to stop bleeding
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

5. Acute Myeloid Leukemia
In AML, the myeloid stem cells
become a type of immature
white blood cell called
myeloblasts (or myeloid
blasts).
These cells are abnormal and
do not become healthy white
blood cells.
Myeloid blasts are abnormal white blood
cells and are not healthy.
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

6. Severity & Progression
Sometimes, too many
stem cells become
abnormal red blood cells
or platelets (leukemia
cells or blasts).
These cells build up in the
bone marrow and blood
resulting in less room for
healthy white blood cells,
red blood cells, and
platelets.
As AML progresses, leukemia cells can spread outside the
blood to other parts of the body. (Scientific Animations, 2017)
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

7. Risk Factors
Male
Smoking
(esp. 60+ y/o)
History of
Chemo or
Radiotherapy
History of
Blood
disorders
Exposure to
Radiation
The following risk factors increase
the chances of being diagnosed
with AML.
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

8. Known Symptoms of AML
FEVER
SHORTNESS OF
BREATH
EASY BRUISING/BLEEDING
PETECHIAE
WEAKNESS/FATIGUE
WEIGHT LOSS
Early signs and symptoms
of AML may be like those
caused by the flu or other
common diseases.
Source: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

9. 32% of Adult
Leukemia
AML makes up
32% of all adult
leukemia cases.
It is one of the
most common
types of
leukemia in
adults.
AML is RARE
Overall, accounting
for only about 1% of
all cancers.
Average Age is 68
years old
Uncommon before the
age of 45, but AML
can occur in children
as well.
1.8% Cancer
Deaths
AML makes up 1.8% of
all cancer deaths,
higher percentage in
males.
Key AML Facts
Source: https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics

10. Oncolytic Virus Treatment
Oncolytic viral therapy is a
new and promising strategy
against cancer. It basically
involves treating cancer using
a modified virus.
Oncolytic viruses (OVs) only
infect cancer cells and not in
normal cells. OVs replicate as
cancer cells multiply, leading to
lysis (destruction) of the tumor
mass.
OVs only infect
cancer cells.
As cancer cells
multiply, so
does OVs.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932159/

11. A non-pathogenic,
proprietary isolate of a
retrovirus. A first-in-class
immuno-oncolytic virus
(IOV).
It is delivered intravenously
for the treatment of solid
tumors and hematological
malignancies.
Myxoma Virus By Oncomyx
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932159/

12. Myxoma Virus By Oncomyx
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932159/

13. Advantages of Myxoma Virus
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932159/
Docile Virus
The virus is safe
and is non-
pathogenic to
human cells.
Domino Effect
As treatment
progresses, the
infection of tumor
cells is amplified.
Trojan-Horse
Viruses can infect
T-cells, when
these cells
replicate, so will
the virus.
Marks Target
Cells
The immune system
makes the ‘cold’
tumor ‘warm’.
Precise
Selective virus that’s
been modified to
target only tumor
cells.

14. Epigenetic therapy is a
relatively new concept. In
this case, it is the use of a
drug to treat AML.
AML is a disease that is
influenced by epigenetic
mechanisms, and epigenetic
therapy offers a potential
way to influence those
pathways directly.
Epigenetic Enzyme Therapy By imago bio
Source: http://www.amsbio.com/epigenetics.aspx

15. IMG-7289 By imago bio
IMG-7289 is a small molecule
that inhibits enzymes
responsible for sustaining self-
renewal in cancer stem/
progenitor cells in the bone
marrow.
The enzyme inhibited is lysine-
specific demethylase 1 (LSD1).
The results are promising, with
high in vivo efficacy in patients
during clinical trials.
As a result of inhibition, the self-
renewal of blasts cells are
disrupted.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932159/

16. USD 1.2
Billion by end
of 2023
Acute Myeloid
Leukemia
Treatment Market
is expected to
reach $ 1.2 billion
by the end of 2023.
Regional Analysis
The Americas will
take the lead
followed by Europe
with APAC as fastest
growing region.
Key Players
• Johnson & Johnson
• Pfizer Inc.
• Celgene Corp.
• Novartis
• Ambit
• Bristol Myers
Approx. 5.3% CAGR
Projected compound
annual growth rate of
5.3% per year during
2017-2023.
Notable Case Studies
Source: https://www.medgadget.com/2019/02/latest-acute-myeloid-leukemia-treatment-therapeutic-
survey-report-2019-technology-treatment-market-share-growth-analysis-and-synthesis-forecast.html

17. Xeraya Capital: Partners in the fight against AML
Xeraya Capital’s commitment to bettering the chances of AML
patients is realized in the recent collaboration with Imago
Biosciences™ and OncoMyx Therapeutics.
We join experienced investors in advancing these therapeutic pipelines
with the ultimate goal of delivering new treatment options to patients.

18. • AML is short for acute myeloid leukemia and is a type of
cancer of the blood and bone marrow.
• AML makes up 32% of adult leukemia cases. It makes up 1.8%
of cancer deaths, and accounts for 1% of all cancers.
• New treatments are being developed, epigenetic enzyme
therapy and oncolytic virus treatments.
• Xeraya Capital joins investors in partnering with Imago
Biosciences™ and OncoMyx Therapeutics to develop these
new treatments.
Conclusion

19. By xeraya capital
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com